BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23269992)

  • 1. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.
    Theurich S; Malcher J; Wennhold K; Shimabukuro-Vornhagen A; Chemnitz J; Holtick U; Krause A; Kobe C; Kahraman D; Engert A; Scheid C; Chakupurakal G; Hallek M; von Bergwelt-Baildon M
    J Clin Oncol; 2013 Feb; 31(5):e59-63. PubMed ID: 23269992
    [No Abstract]   [Full Text] [Related]  

  • 2. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.
    Younes A
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):27-32. PubMed ID: 24287065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity.
    Theurich S; Wennhold K; Wedemeyer I; Rothe A; Hübel K; Shimabukuro-Vornhagen A; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
    Transplantation; 2013 Aug; 96(3):e16-8. PubMed ID: 23917689
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.
    Gopal AK; Ramchandren R; O'Connor OA; Berryman RB; Advani RH; Chen R; Smith SE; Cooper M; Rothe A; Matous JV; Grove LE; Zain J
    Blood; 2012 Jul; 120(3):560-8. PubMed ID: 22510871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
    Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
    Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
    Pham A; Chen R
    Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brentuximab vedotin for the treatment of CD30+ lymphomas.
    Foyil KV; Bartlett NL
    Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):20. PubMed ID: 25768999
    [No Abstract]   [Full Text] [Related]  

  • 10. Brentuximab vedotin for Hodgkin lymphoma who had failed allogeneic stem cell transplantation: a multicenter retrospective study.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):12-4. PubMed ID: 25768995
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of relapsed Hodgkin lymphoma after autologous stem cell transplantation].
    Illés Á; Simon Z; Udvardy M; Magyari F; Jóna Á; Miltényi Z
    Orv Hetil; 2017 Aug; 158(34):1338-1345. PubMed ID: 28823212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation.
    Tsirigotis P; Danylesko I; Gkirkas K; Shem-Tov N; Yerushalmi R; Stamouli M; Avigdor A; Spyridonidis A; Gauthier J; Goldstein G; Apostolidis J; Mohty M; Shimoni A; Nagler A
    Bone Marrow Transplant; 2016 Oct; 51(10):1313-1317. PubMed ID: 27183095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
    N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
    Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
    Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation.
    Baxley AA; Kumm DE; Bishop CB; Medina PJ; Holter-Chakrabarty J
    J Oncol Pharm Pract; 2013 Sep; 19(3):279-83. PubMed ID: 23154572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    Howell M; Gibb A; Radford J; Linton K
    Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
    [No Abstract]   [Full Text] [Related]  

  • 17. Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.
    Arora A; Bhatt VR; Liewer S; Armitage JO; Bociek RG
    Eur J Haematol; 2015 Oct; 95(4):361-4. PubMed ID: 25892213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma.
    Dozzo M; Zaja F; Volpetti S; Sperotto A; Magli A; Fanin R
    Am J Hematol; 2015 Apr; 90(4):E73. PubMed ID: 25546725
    [No Abstract]   [Full Text] [Related]  

  • 19. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French Name Patient Program experience in 241 patients.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):4-5. PubMed ID: 25768991
    [No Abstract]   [Full Text] [Related]  

  • 20. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
    Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
    Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.